Aimovig: A New Prescription Drug for Migraines

Aimovig: A New Prescription Drug for Migraines


The Food and Drug Administration (FDA) recently approved Aimovig, a new self-injectable drug to prevent migraine headaches. At this time, BlueCross BlueShield of South Carolina and BlueChoice® HealthPlan are not adding this drug to our formularies until our Pharmacy & Therapeutics (P&T) Committee reviews the product and clinical outcomes. 

What you need to know:

  • If a recommendation is made to add Aimovig to our formulary, we will designate it as a specialty pharmacy drug requiring prior authorization through CVS Specialty, our preferred specialty pharmacy vendor. CVS Specialty is a division of CVS Health, an independent company that provides pharmacy benefit management and specialty pharmacy services on behalf of BlueCross and BlueChoice. We expect coverage to be limited to patients who are under the care of a neurologist and who have tried and failed 12 weeks of prophylactic therapy. 
  • If you currently have a patient you believe needs this medication, you may request a formulary exception by calling the medical plan’s precertification number on the back of the member’s ID card.   

If you have questions about this bulletin, you may contact Provider Education at 803-264-4730 or submit your questions using the Provider Education Contact Form

BlueChoice® HealthPlan of South Carolina is an independent licensee of the Blue Cross and Blue Shield Association.